{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:42:50Z","timestamp":1790764970087,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Angelo Donghia Foundation"},{"name":"Omeros Inc."},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL148123"],"award-info":[{"award-number":["HL148123"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL123605"],"award-info":[{"award-number":["HL123605"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM114731"],"award-info":[{"award-number":["GM114731"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,16]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Involvement of the alternative complement pathway (AP) in microvascular endothelial cell (MVEC) injury characteristic of a thrombotic microangiopathy (TMA) is well documented. However, the role of the lectin pathway (LP) of complement has not been explored. We examined mannose-binding lectin associated serine protease (MASP2), the effector enzyme of the LP, in thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome and post-allogeneic hematopoietic stem cell transplantation (alloHSCT) TMAs. Plasma MASP2 and terminal complement component sC5b-9 levels were assessed by enzyme-linked immunosorbent assay (ELISA). Human MVEC were exposed to patient plasmas, and the effect of the anti-MASP2 human monoclonal antibody narsoplimab on plasma-induced MVEC activation was assessed by caspase 8 activity. MASP2 levels were highly elevated in all TMA patients versus controls. The relatively lower MASP2 levels in alloHSCT patients with TMAs compared to levels in alloHSCT patients who did not develop a TMA, and a significant decrease in variance of MASP2 levels in the former, may reflect MASP2 consumption at sites of disease activity. Plasmas from 14 of the 22 TMA patients tested (64%) induced significant MVEC caspase 8 activation. This was suppressed by clinically relevant levels of narsoplimab (1\u00b72\u00a0\u03bcg\/ml) for all 14 patients, with a mean 65\u00b77% inhibition (36.8\u201399.4%; P\u00a0&amp;lt;\u00a00\u00b70001). In conclusion, the LP of complement is activated in TMAs of diverse etiology. Inhibition of MASP2 reduces TMA plasma-mediated MVEC injury in vitro. LP inhibition therefore may be of therapeutic benefit in these disorders.<\/jats:p>","DOI":"10.1111\/cei.13497","type":"journal-article","created":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T11:22:50Z","timestamp":1595071370000},"page":"96-104","source":"Crossref","is-referenced-by-count":54,"title":["MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab"],"prefix":"10.1093","volume":"203","author":[{"given":"S","family":"Elhadad","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Chapin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, USA"},{"name":"CRISPR Therapeutics, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Copertino","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Van Besien","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Ahamed","sequence":"additional","affiliation":[{"name":"Oklahoma Medical Research Foundation, Oklahoma City, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8274-3144","authenticated-orcid":false,"given":"J","family":"Laurence","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,5]]},"reference":[{"key":"2021121023175569500_cei13497-bib-0001","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/cei.12093","article-title":"Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases","volume":"173","author":"Frauenknecht","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"2021121023175569500_cei13497-bib-0002","first-page":"1","article-title":"The lectin pathway of complement and rheumatic heart disease","volume":"2","author":"Beltrame","year":"2015","journal-title":"Front Ped"},{"key":"2021121023175569500_cei13497-bib-0003","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1161\/STROKEAHA.116.012407","article-title":"Lectin complement pathway and its bloody interactions in brain ischemia","volume":"47","author":"Fumagalli","year":"2016","journal-title":"Stroke"},{"key":"2021121023175569500_cei13497-bib-0004","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.4049\/jimmunol.0903678","article-title":"Molecular intercommunication between the complement and coagulation systems","volume":"185","author":"Amara","year":"2010","journal-title":"J Immunol"},{"key":"2021121023175569500_cei13497-bib-0005","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, atypical HUS and TTP are all diseases of complement activation","volume":"8","author":"Noris","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"2021121023175569500_cei13497-bib-0006","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/jth.13696","article-title":"Von Willebrand factor and inflammation","volume":"15","author":"Kawecki","year":"2017","journal-title":"J Thromb Hemost"},{"key":"2021121023175569500_cei13497-bib-0007","first-page":"1","article-title":"Be on target: strategies of targeting alternative and lectin pathway components in complement-mediated diseases","volume":"9","author":"Dodo","year":"2018","journal-title":"Front Immunol"},{"key":"2021121023175569500_cei13497-bib-0008","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.molimm.2009.09.005","article-title":"The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification","volume":"47","author":"Harboe","year":"2009","journal-title":"Mol Immunol"},{"key":"2021121023175569500_cei13497-bib-0009","first-page":"845","article-title":"Breakdown products of C3 and Factor B in hemolytic-uremic syndrome","volume":"89","author":"Kim","year":"1977","journal-title":"J Lab Clin Med"},{"key":"2021121023175569500_cei13497-bib-0010","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP","volume":"123","author":"Cateland","year":"2014","journal-title":"Blood"},{"key":"2021121023175569500_cei13497-bib-0011","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1538-7836.2012.04674.x","article-title":"Complement activation in thrombotic thrombocytopenic purpura","volume":"10","author":"Reti","year":"2012","journal-title":"J Thromb Hemost"},{"key":"2021121023175569500_cei13497-bib-0012","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2006-939768","article-title":"Terminal complement complex (C5b\u20139) in children with recurrent hemolytic uremic syndrome","volume":"32","author":"Prufer","year":"2006","journal-title":"Sem Thromb Hemost"},{"key":"2021121023175569500_cei13497-bib-0013","first-page":"565","article-title":"Hematopoietic transplant-associated microangiopathy: case report and review of diagnosis and treatment","volume":"12","author":"Chapin","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"2021121023175569500_cei13497-bib-0014","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/TP.0b013e31829807aa","article-title":"Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"96","author":"Laskin","year":"2013","journal-title":"Transplantation"},{"key":"2021121023175569500_cei13497-bib-0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10875-019-00714-4","article-title":"Should MASP-2 deficiency be considered a primary immunodeficiency? Relevance of the lectin pathway","volume":"40","author":"Garcia-Laorden","year":"2020","journal-title":"J Clin Immunol"},{"key":"2021121023175569500_cei13497-bib-0016","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/blood-2007-10-119552","article-title":"Synergistic interactions between interferon-\u03b3 and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis","volume":"112","author":"Stefanescu","year":"2008","journal-title":"Blood"},{"issue":"11 S1","key":"2021121023175569500_cei13497-bib-0017","first-page":"2","article-title":"Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis","volume":"14","author":"Laurence","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"2021121023175569500_cei13497-bib-0018","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/TP.0b013e3181f24e8d","article-title":"Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation","volume":"90","author":"Cho","year":"2010","journal-title":"Transplantation"},{"key":"2021121023175569500_cei13497-bib-0019","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.4049\/jimmunol.171.3.1526","article-title":"TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells","volume":"171","author":"Li","year":"2003","journal-title":"J Immunol"},{"key":"2021121023175569500_cei13497-bib-0020","volume-title":"Improved survival following OMS721 treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA)","author":"Rambaldi","year":"2018"},{"key":"2021121023175569500_cei13497-bib-0021","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.transci.2016.04.007","article-title":"New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"54","author":"Jodele","year":"2016","journal-title":"Transf Apheresis Sci"},{"key":"2021121023175569500_cei13497-bib-0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.02153","article-title":"The role of complement activating collectins and associated serine proteases in patients with hematologic malignancies, receiving high-dose chemotherapy, and autologous hematopoietic stem cell transplantations (auto-HSCT)","volume":"9","author":"Swierzko","year":"2018","journal-title":"Front Immunol"},{"key":"2021121023175569500_cei13497-bib-0023","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/pbc.22028","article-title":"Prognosis in pediatric hematologic malignancies is associated with serum concentration of mannose-binding lectin-associated serine protease-2 (MASP-2)","volume":"53","author":"Zehnder","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"2021121023175569500_cei13497-bib-0024","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ijcard.2011.11.032","article-title":"MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans","volume":"166","author":"Zhang","year":"2013","journal-title":"Int J Cardiol"},{"key":"2021121023175569500_cei13497-bib-0025","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0002-9440(10)65026-2","article-title":"Complement activation after oxidative stress. Role of the lectin complement pathway","volume":"156","author":"Collard","year":"2000","journal-title":"Am J Pathol"},{"key":"2021121023175569500_cei13497-bib-0026","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2017-000652","article-title":"Cardioprotection by an anti-MASP-2 antibody in a murine model of myocardial infarction","volume":"5","author":"Clark","year":"2018","journal-title":"Open Heart"},{"key":"2021121023175569500_cei13497-bib-0027","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1055\/s-0038-1654714","article-title":"The lectin pathway in thrombotic conditions \u2013 a systematic review","volume":"118","author":"Larsen","year":"2018","journal-title":"Thromb Hemost"},{"key":"2021121023175569500_cei13497-bib-0028","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1182\/blood-2007-08-106153","article-title":"Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation","volume":"111","author":"Stahl","year":"2008","journal-title":"Blood"},{"key":"2021121023175569500_cei13497-bib-0029","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An ex vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kid Dis"},{"key":"2021121023175569500_cei13497-bib-0030","volume-title":"Resolution of acute kidney injury secondary to TA-TMA by the anti-MASP-2 monoclonal antibody OMS721 in a pediatric HSCT recipient","author":"Zecca","year":"2017"},{"key":"2021121023175569500_cei13497-bib-0031","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10875-019-00714-4","article-title":"Should MASP-2 deficiency be considered a primary immunodeficiency? Relevance of the lectin pathway","volume":"40","author":"Garcia-Laorden","year":"2020","journal-title":"J Clin Immunol"},{"key":"2021121023175569500_cei13497-bib-0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","article-title":"Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases","volume":"220","author":"Magro","year":"2020","journal-title":"Transl Res"},{"key":"2021121023175569500_cei13497-bib-0033","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.bbmt.2017.08.019","article-title":"Thrombotic microangiopathy after allogeneic stem cell transplantation: a comparison of eculizumab therapy and conventional therapy","volume":"23","author":"Bohl","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021121023175569500_cei13497-bib-0034","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2017-10-811943","article-title":"Complement and coagulation: so close, yet so far","volume":"130","author":"Schmidt","year":"2017","journal-title":"Blood"},{"key":"2021121023175569500_cei13497-bib-0035","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2016-11-749879","article-title":"Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development","volume":"129","author":"Subramaniam","year":"2017","journal-title":"Blood"},{"key":"2021121023175569500_cei13497-bib-0036","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.molimm.2015.03.244","article-title":"Complement and platelets: mutual interference in the immune network","volume":"67","author":"Speth","year":"2015","journal-title":"Mol Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.13497","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cei.13497","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cei.13497","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/203\/1\/96\/41635184\/cei13497.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/203\/1\/96\/41635184\/cei13497.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:25:07Z","timestamp":1641054307000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/203\/1\/96\/6401306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,8,5]]},"published-print":{"date-parts":[[2020,12,16]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.13497","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,8,5]]}}}